指南与共识关节外科骨质疏松与代谢性骨病

关节置换候选者围手术期骨骼优化:FEMECOT、AMMOM、ACOMM、SCCOT、SECOT、SEFRAOS、SEIOMM的循证联合立场声明

Evidence-based joint statement position of perioperative bone optimization in the arthroplasty candidate, from FEMECOT, AMMOM, ACOMM, SCCOT, SECOT, SEFRAOS, SEIOMM.
指南 / 共识 · Osteoporos Int · 2025-02-12

七个国家学会针对关节置换候选者围手术期骨骼优化制定联合立场声明,通过范围综述、系统综述与Meta分析及改良德尔菲法形成五条推荐。推荐包括择期关节置换患者应接受骨骼健康评估、术中见骨质量差且未及时评估者应完成含DXA的完整评估、发现低骨密度或骨质疏松应纠正骨丢失相关因素并启动抗骨质疏松治疗、诊断不应延迟手术、通过DXA方案监测中央及假体周围骨密度。

要点

  • 择期关节置换候选者中近三分之二存在低骨密度,骨质疏松者仅32.8%在手术时接受治疗。
  • 推荐择期关节置换患者接受骨骼健康评估(BHA)。
  • 诊断骨质疏松或低骨密度不应延迟关节置换手术。

核心结论

  • 围手术期骨骼优化应考虑用于所有关节置换候选者,骨科医生和多学科团队应鼓励通过筛查骨丢失相关因素、诊断骨质疏松并按当前国际指南启动治疗。
  • 遵循这些推荐可减少假体周围骨丢失、并发症和无菌性翻修率,但仍需更多研究理解骨质疏松及其治疗对关节置换结局和长期生存的影响。

研究设计与样本

  • 由7个国家学会(FEMECOT、AMMOM、ACOMM、SCCOT、SECOT、SEFRAOS、SEIOMM)组成小组制定关于关节置换候选者骨质疏松诊断和围手术期骨骼优化的联合立场声明。
  • 对现有文献进行范围综述,随后进行系统综述和Meta分析,之后采用改良德尔菲法汇集各方立场。

主要发现

  • 接受择期关节置换手术的患者中近三分之二存在低骨密度,其中骨量减少占38.5%、骨质疏松占24.8%。
  • 骨质疏松患者中仅32.8%在手术时接受了治疗。
  • 使用抗骨吸收剂和骨合成代谢剂已被证明可减少关节置换术后假体周围骨丢失、并发症和无菌性翻修率。

关键数值与推荐

  • 推荐1:计划接受择期关节置换的患者应接受骨骼健康评估(BHA)。
  • 推荐2:若术中观察到骨质量差且未及时进行骨骼健康评估,必须完成包括DXA扫描在内的完整BHA。
  • 推荐3:关节置换候选者若发现低骨密度或骨质疏松,应纠正骨丢失相关因素,并在关节置换术前或术后立即启动适当的骨质疏松治疗。
  • 推荐4:关节置换候选者中,骨质疏松或低骨密度的诊断不应延迟手术。
  • 推荐5:通过DXA方案监测中央和假体周围骨密度有助于识别有危险因素或骨质疏松患者的中央及假体周围区域骨丢失。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of patients living with joint replacements is increasing. Nearly two-thirds of patients undergoing elective arthroplasty procedures have low bone mineral density (LBMD), defined as osteopenia in 38.5% and osteoporosis in 24.8%; among those with osteoporosis, only 32.8% received treatment at the time of surgery. MATERIALS AND METHODS: A group of 7 national societies (FEMECOT, AMMOM, ACOMM, SCCOT, SECOT, SEFRAOS, SEIOMM) developed a joint statement position on the diagnosis of osteoporosis and perioperative bone optimization in candidates for arthroplasty "Arthroplasty Bone Optimization." We performed a scoping review of the available literature, followed by a systematic review and meta-analysis. Subsequently, a Delphi-modified method was used to gather the different positions. RESULTS: After analyzing the literature, we came up with five recommendations: (1) Patients scheduled for elective arthroplasty should undergo a bone health assessment (BHA). (2) If poor bone quality is observed during surgery and a bone health assessment has not been conducted promptly, a complete BHA, including a DXA scan, is imperative. (3) In the arthroplasty candidate, if LBMD or osteoporosis are noticed, bone loss-related factors should be corrected, and appropriate treatment for osteoporosis should be started before or right after arthroplasty. The use of anti-resorptive and bone anabolic agents has been shown to reduce periprosthetic bone loss, complications, and non-septic revision rates after joint arthroplasty. (4) In arthroplasty candidates, the diagnosis of osteoporosis or low bone mineral density (LBMD) should not delay the surgery. (5) Monitoring central and periprosthetic bone mineral density through DXA protocols can help identify bone loss in central and periprosthetic areas in patients with risk factors or osteoporosis. CONCLUSIONS: Perioperative bone optimization should be considered in all patients who are candidates for arthroplasty. The orthopedic surgeon and multidisciplinary team should be encouraged to diagnose and treat the arthroplasty candidates' bone by screening for bone loss-related factors and diagnosing osteoporosis and starting treatment according to the current international guidelines. Following these recommendations could reduce periprosthetic bone loss, complications, and aseptic revision rates following arthroplasty surgery. More research is needed to understand the implications of osteoporosis and its treatment for joint replacement outcomes and long-term survival.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Enrique LR, Francisco TN, Iñigo EF, et al. Evidence-based joint statement position of perioperative bone optimization in the arthroplasty candidate, from FEMECOT, AMMOM, ACOMM, SCCOT, SECOT, SEFRAOS, SEIOMM. Osteoporos Int. 2025. PMID: 39934392. doi:10.1007/s00198-025-07411-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。